Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 12, 2026
- AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027.
- 10-Q report · filed Nov 12, 2026
- AnaptysBio reported $30.3 million in collaboration revenue for the three months ended September 30, 2026, down from $76.3 million, while Jemperli received accelerated FDA approval for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer.
The audio replay and transcript follow the call.